Fig. 7
pMHCII-NPs versus the standard of care in PBC. a–c Effects of treatment with PDC166–181/IAg7-NPs or the standard of care in PBC (UDCA) on serum ALT (a; n = 4, 5, and 7, from left to right, respectively), macroscopic (b; n = 9, 7 and 7, from left to right, respectively) and microscopic (c; n = 5/group) disease scores, when treatment is initiated early on in the disease process (from 6 to 20 weeks of age; twice a week for PDC166–181/IAg7-NPs or continuously for UDCA). d Percentages of tetramer+CD4+ T-cells in the mice studied in a–c. Data correspond to n = 8, 7 and 7 mice from left to right, respectively. Data in a–d are from 2 to 3 experiments/group. e–g Effects of treatment with PDC166–181/IAg7-NPs or UDCA on serum ALT levels (e; n = 7, 15, and 8, from left to right, respectively), macroscopic (f; n = 7, 8 and 18, from left to right, respectively) and microscopic (g; n = 6, 8 and 7 from left to right, respectively) disease scores, when treatment is initiated at advanced stages of the disease process (from 24 to 33 weeks of age; twice a week for PDC166–181/IAg7-NPs or continuously for UDCA). h Percentages of tetramer+CD4+ T-cells in the mice studied in e–g. Data correspond to n = 6, 9 and 8 mice from left to right, respectively. Data in e–h are from 2 to 3 experiments/group. Averaged data correspond the mean ± SEM. P values were compared via Mann–Whitney U
